Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)

Sergio Leonardi, Sunil V. Rao, Robert A. Harrington, Deepak L. Bhatt, C. Michael Gibson, Matthew T. Roe, Janusz Kochman, Kurt Huber, Uwe Zeymer, Mina Madan, Daniel D. Gretler, Matthew W. McClure, Gayle E. Paynter, Vivian Thompson, Robert C. Welsh

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Despite current dual-antiplatelet therapy with aspirin and clopidogrel, adverse clinical events continue to occur during and after percutaneous coronary intervention (PCI). The failure of clopidogrel to provide optimal protection may be related to delayed onset of action, interpatient variability in its effect, and an insufficient level of platelet inhibition. Furthermore, the irreversible binding of clopidogrel to the P2Y12 receptor for the life span of the platelet is associated with increased bleeding risk especially during urgent or emergency surgery. Novel antiplatelet agents are required to improve management of patients undergoing PCI. Elinogrel is a potent, direct-acting (ie, non-prodrug), selective, competitive, and reversible P2Y 12 inhibitor available in both intravenous and oral formulations. The INNOVATE-PCI study is a phase 2 randomized, double-blind, clopidogrel- controlled trial to evaluate the safety, tolerability, and preliminary efficacy of this novel antiplatelet agent in patients undergoing nonurgent PCI.

Original languageEnglish
Pages (from-to)65-72
Number of pages8
JournalAmerican Heart Journal
Volume160
Issue number1
DOIs
Publication statusPublished - Jul 2010

Fingerprint

clopidogrel
Percutaneous Coronary Intervention
Intravenous Administration
Oral Administration
Platelet Aggregation Inhibitors
Blood Platelets
Aspirin
Emergencies
Hemorrhage
Safety
elinogrel

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). / Leonardi, Sergio; Rao, Sunil V.; Harrington, Robert A.; Bhatt, Deepak L.; Gibson, C. Michael; Roe, Matthew T.; Kochman, Janusz; Huber, Kurt; Zeymer, Uwe; Madan, Mina; Gretler, Daniel D.; McClure, Matthew W.; Paynter, Gayle E.; Thompson, Vivian; Welsh, Robert C.

In: American Heart Journal, Vol. 160, No. 1, 07.2010, p. 65-72.

Research output: Contribution to journalArticle

Leonardi, Sergio ; Rao, Sunil V. ; Harrington, Robert A. ; Bhatt, Deepak L. ; Gibson, C. Michael ; Roe, Matthew T. ; Kochman, Janusz ; Huber, Kurt ; Zeymer, Uwe ; Madan, Mina ; Gretler, Daniel D. ; McClure, Matthew W. ; Paynter, Gayle E. ; Thompson, Vivian ; Welsh, Robert C. / Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). In: American Heart Journal. 2010 ; Vol. 160, No. 1. pp. 65-72.
@article{0dea3b73301143289b82c0f758b521e4,
title = "Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)",
abstract = "Despite current dual-antiplatelet therapy with aspirin and clopidogrel, adverse clinical events continue to occur during and after percutaneous coronary intervention (PCI). The failure of clopidogrel to provide optimal protection may be related to delayed onset of action, interpatient variability in its effect, and an insufficient level of platelet inhibition. Furthermore, the irreversible binding of clopidogrel to the P2Y12 receptor for the life span of the platelet is associated with increased bleeding risk especially during urgent or emergency surgery. Novel antiplatelet agents are required to improve management of patients undergoing PCI. Elinogrel is a potent, direct-acting (ie, non-prodrug), selective, competitive, and reversible P2Y 12 inhibitor available in both intravenous and oral formulations. The INNOVATE-PCI study is a phase 2 randomized, double-blind, clopidogrel- controlled trial to evaluate the safety, tolerability, and preliminary efficacy of this novel antiplatelet agent in patients undergoing nonurgent PCI.",
author = "Sergio Leonardi and Rao, {Sunil V.} and Harrington, {Robert A.} and Bhatt, {Deepak L.} and Gibson, {C. Michael} and Roe, {Matthew T.} and Janusz Kochman and Kurt Huber and Uwe Zeymer and Mina Madan and Gretler, {Daniel D.} and McClure, {Matthew W.} and Paynter, {Gayle E.} and Vivian Thompson and Welsh, {Robert C.}",
year = "2010",
month = "7",
doi = "10.1016/j.ahj.2010.04.008",
language = "English",
volume = "160",
pages = "65--72",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)

AU - Leonardi, Sergio

AU - Rao, Sunil V.

AU - Harrington, Robert A.

AU - Bhatt, Deepak L.

AU - Gibson, C. Michael

AU - Roe, Matthew T.

AU - Kochman, Janusz

AU - Huber, Kurt

AU - Zeymer, Uwe

AU - Madan, Mina

AU - Gretler, Daniel D.

AU - McClure, Matthew W.

AU - Paynter, Gayle E.

AU - Thompson, Vivian

AU - Welsh, Robert C.

PY - 2010/7

Y1 - 2010/7

N2 - Despite current dual-antiplatelet therapy with aspirin and clopidogrel, adverse clinical events continue to occur during and after percutaneous coronary intervention (PCI). The failure of clopidogrel to provide optimal protection may be related to delayed onset of action, interpatient variability in its effect, and an insufficient level of platelet inhibition. Furthermore, the irreversible binding of clopidogrel to the P2Y12 receptor for the life span of the platelet is associated with increased bleeding risk especially during urgent or emergency surgery. Novel antiplatelet agents are required to improve management of patients undergoing PCI. Elinogrel is a potent, direct-acting (ie, non-prodrug), selective, competitive, and reversible P2Y 12 inhibitor available in both intravenous and oral formulations. The INNOVATE-PCI study is a phase 2 randomized, double-blind, clopidogrel- controlled trial to evaluate the safety, tolerability, and preliminary efficacy of this novel antiplatelet agent in patients undergoing nonurgent PCI.

AB - Despite current dual-antiplatelet therapy with aspirin and clopidogrel, adverse clinical events continue to occur during and after percutaneous coronary intervention (PCI). The failure of clopidogrel to provide optimal protection may be related to delayed onset of action, interpatient variability in its effect, and an insufficient level of platelet inhibition. Furthermore, the irreversible binding of clopidogrel to the P2Y12 receptor for the life span of the platelet is associated with increased bleeding risk especially during urgent or emergency surgery. Novel antiplatelet agents are required to improve management of patients undergoing PCI. Elinogrel is a potent, direct-acting (ie, non-prodrug), selective, competitive, and reversible P2Y 12 inhibitor available in both intravenous and oral formulations. The INNOVATE-PCI study is a phase 2 randomized, double-blind, clopidogrel- controlled trial to evaluate the safety, tolerability, and preliminary efficacy of this novel antiplatelet agent in patients undergoing nonurgent PCI.

UR - http://www.scopus.com/inward/record.url?scp=77955677366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955677366&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2010.04.008

DO - 10.1016/j.ahj.2010.04.008

M3 - Article

VL - 160

SP - 65

EP - 72

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 1

ER -